Activity and toxicity of GI147211 in breast, colorectal and non-small-cell lung cancer patients: An EORTC-ECSG phase II clinical study

Annals of Oncology

Volumn 11, Issue 7, 2000, Pages 793-797

  Gamucci, T ^a   Paridaens, R ^b   Heinrich, B ^c   Schellens, J H ^d   Pavlidis, N ^e   Verweij, J ^f   Sessa, C ^g   Kaye, S ^h   Roelvink, M ⁱ   Wanders, J ^j   Hanauske, A ^b  

^a REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

^b UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^c TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^d NETHERLANDS CANCER INSTITUTE   (Netherlands)

^e UNIVERSITY HOSPITAL OF IOANNINA   (Greece)

^f ERASMUS MEDICAL CENTER   (Netherlands)

^g SAN GIOVANNI HOSPITAL   (Switzerland)

^h UNIVERSITY OF GLASGOW   (United Kingdom)

ⁱ EORTC New Drug Development Office (NDDO)   (Netherlands)

^j VU UNIVERSITY MEDICAL CENTER   (Netherlands)

more..

Author keywords

Breast cancer; Camptothecins; Colorectal cancer; GI147211; Non small cell lung cancer; Topoisomerase I

Indexed keywords

CAMPTOTHECIN DERIVATIVE; LURTOTECAN;

ADULT; AGED; ALOPECIA; ANEMIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; ASTHENIA; BREAST CANCER; CANCER CHEMOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; COLORECTAL CANCER; DOSE RESPONSE; DRUG RESPONSE; FEBRILE NEUTROPENIA; FEMALE; GASTROINTESTINAL SYMPTOM; HUMAN; LUNG NON SMALL CELL CANCER; MALE; MULTICENTER STUDY; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; THROMBOCYTOPENIA; TREATMENT OUTCOME;

ADULT; AGED; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CAMPTOTHECIN; CARCINOMA, NON-SMALL-CELL LUNG; COLORECTAL NEOPLASMS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; LUNG NEOPLASMS; MALE; MIDDLE AGED; TREATMENT OUTCOME;

EID: 0033821727     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1008373031714     Document Type: Article

References (14)

1. Topoisomerase I inhibition by the camptothecin analog GI147211C
2. Topoisomerase interactive agents
3. Preliminary pharmacologic and clinical evaluation of camptothecin sodium (NSC-100880)
4. Phase I clinical trial of weekly and daily treatment with camptothecin (NSC-100800): Correlation with preclinical studies
5. Plasma camptothecin (NSC 100880) levels during a five-day course of treatment: Relation to dose and toxicity
6. Topoisomerase I inhibitors: Topotecan and irinotecan
7. Preclinical antitumor activity of a novel water-soluble camptothecin analog (GI147211C)
8. In vivo antitumor activity of two new seven-substituted water-soluble camptothecin analogues
9. Phase I and pharmacokinetic study of GI147211, a water-soluble camptothecin analogue, administered for five consecutive days every three weeks
10. Phase I and pharmacological study of the new topoisomerase I inhibitor GI147211, using a daily x 5 intravenous administration
11. Comprehensive criteria for assessing therapy-induced toxicity
12. Reporting results of cancer treatment
13. A phase I clinical and pharmacokinetic study of the new topoisomerase inhibitor GI147211 given as a 72-hour continuous infusion
14. Phase I trial of the topoisomerase I inhibitor GG211 as a 21-day continuous infusion